Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy

BACKGROUND: A few tau immunotherapies are now in clinical trials with several more likely to be initiated in the near future. A priori, it can be anticipated that an antibody which broadly recognizes various pathological tau aggregates with high affinity would have the ideal therapeutic properties....

Descripción completa

Detalles Bibliográficos
Autores principales: Congdon, Erin E., Lin, Yan, Rajamohamedsait, Hameetha B., Shamir, Dov B., Krishnaswamy, Senthilkumar, Rajamohamedsait, Wajitha J., Rasool, Suhail, Gonzalez, Veronica, Levenga, Josien, Gu, Jiaping, Hoeffer, Charles, Sigurdsson, Einar M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5006503/
https://www.ncbi.nlm.nih.gov/pubmed/27578006
http://dx.doi.org/10.1186/s13024-016-0126-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5006503/
https://www.ncbi.nlm.nih.gov/pubmed/27578006
http://dx.doi.org/10.1186/s13024-016-0126-z

Ejemplares similares